Abstract: Systems and methods for authenticating and/or routing a digital signal are provided. A system may include a central database configured to store a set of signature brain wave responses as part of a profile of a user. The system may include a transaction device, a sensory device, and an EEG device. When a transaction request is received from the user, the system may be configured to present the user with a sensory prompt, detect a response of the user to the first sensory prompt, compare the response to the signature response in the profile associated with the sensory prompt, and, when the response matches the signature response within a predetermined delta, authenticate and/or route the transaction request.

Abstract: In an example, the deodorant includes a solution. The solution includes a diluent and at least one fruit acid (i.e., at least one alpha hydroxy acid). The solution may also include at least one probiotic. In an embodiment, the deodorant may also include at least one applicator that is configured to hold the solution, such as at least one pad. In an embodiment, a method of using the deodorant may include contacting the armpit (e.g., axilla) or another region of the body with the deodorant to control the body odor of the individual.

Abstract: The present disclosure relates to a formulation including: a) a dendron of Formula I; b) at least one bio-therapeutic; c) at least one buffer; and d) at least one salt, wherein the bio-therapeutic to dendron molar ratio is in the range of 1:0.5-1:3. The dendron stabilizes the bio-therapeutic in the formulation at a temperature of up to 55° C.

Abstract: A method for applying a cosmetic composition to skin is disclosed. The method can include applying a first composition to skin that includes at least about 50% by weight of a volatile hydrocarbon, a film former, a solvent comprising an ester group, and a combination of ultraviolet A (UVA) and ultraviolet B (UVB) sunscreen agents, wherein the UVA sunscreen agent comprises 4-tert-butyl-4?-methoxydibenzoylmethane, wherein the first composition has an SPF of at least about 15 and a PFA of at least about 5, and wherein the first composition dries within two minutes after topical application to skin, and subsequently applying the cosmetic composition onto the first composition.

Abstract: The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.

Abstract: An aqueous cosmetic includes water, a polyhydric alcohol and carminic acid. A content of the carminic acid is greater than or equal to 0.2 mass % and less than 2 mass % based on a total amount of the aqueous cosmetic.

Abstract: The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.

Abstract: A tissue graft for soft tissue repair or reconstruction comprising a sheet of a biopolymer-based matrix having a plurality of small perforations and a plurality of large perforations. The small perforations are sized to facilitate clotting and granulation tissue development within the perforations which, in turn, facilitates revascularization and cell repopulation in the patient. The large perforations are sized to reduce the occurrence of clotting and granulation tissue development within the perforations so that extravascular tissue fluids accumulating at the implant site can drain through the tissue graft. The large perforations enhance mammal tissue anchoring by permitting mammal tissue to compress into the perforations increasing mammal tissue contact area.

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

Abstract: Nano- to microscale liquid coacervate particles are provided. The liquid coacervate particles are produced by a process including stimulating a population of liquid droplets containing one or a mixture of components to induce a phase separation point of a first component, and maintaining stimulation at the phase separation point to form a coacervate domain of the first component within each of the droplets to form the liquid coacervate particles. The self-assembled nano, meso, micro and macro liquid coacervate particles and related coated substrates can have utility in drug delivery, bioanalytical systems, controlled cell culture, tissue engineering, biomanufacturing and drug discovery.

Abstract: The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.

Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

Abstract: Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in a primarily liquid based polyol carrier so that chelated metal oxide particles form a stable complex suspension that is optionally an alkaline based aqueous silver oxide dispersion. The liquid composition can be subsequently added to any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system.

Abstract: An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Abstract: Described herein are methods for modulating expression of a gene in a cell by contacting the cell with a gene modulation composition, such as a composition including an electrolyzed saline solution.

Abstract: A composition and methods for lubricating mucous membranes including reproductive tissue with a topical lubricant and at least one cannabinoid. Cannabis and cannabinoids are solubilized and combined with water-based personal lubricants.

Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Abstract: The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy and having improved properties.

Abstract: The present disclosure relates to delivery systems. More particularly, the present disclosure relates to a process for releasing an active ingredient including a step of contacting a powdered composition with a medium having a pH?7. The powdered composition includes granules made of a water soluble polymer matrix, an oil phase dispersed in said matrix and carbonate particles. Consumer products such as an antiperspirant or deodorant composition or a powder soft drink beverage composition including the powdered composition are also object of the present disclosure.

Abstract: The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.

Abstract: A process is provided for separating hydrophobic material from a mixture of hydrophobic and hydrophilic material using peptide-based amphiphilic organogelators.

Abstract: Oral medicament comprising an osmotic laxative incorporated into a matrix based on plant fats. The present invention relates to an oral pharmaceutical composition comprising: between 30 and 55% by weight of said pharmaceutical composition of micronized anhydrous macrogol; and between 45 and 70% by weight of the pharmaceutical composition of a carrier consisting of an anhydrous hydrophobic lipid coating based on fatty compounds of plant origin, having a melting point of between 36 and 38° C., and to the use thereof as laxative. Said composition enables the reduction in the daily dosage of macrogol by preserving the osmotic pressure thereof as far as the colon, the site of therapeutic action of osmotic laxatives; said carrier protects the macrogol from a reduction, due to the moisture in the digestive tract, in the osmotic pressure.

Abstract: The present disclosure relates to pharmaceutical compositions comprising zinc, copper, at least one micronutrient, and a pharmaceutically acceptable excipient; and comprising administering, to a subject in need thereof, a pharmaceutical composition comprising zinc, copper, at least one micronutrient, and a pharmaceutically acceptable excipient.

Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.

Abstract: The present disclosure provides an oral liquid composition comprising valsartan with enhanced solubility and stability. Also, provided herein are methods of using the oral liquid compositions for the treatment of hypertension, treatment of heart failure and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.

Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.

Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.

Abstract: Provided herein are water soluble solid form compositions including a curcuminoid; and a solubilizer selected from one or more of methylsulfonylmethane (MSM) and steviol glycoside; glycerol polyethylene glycol hydroxystearate (GPGH) and steviol glycoside; fatty acid glycerol polyglycoester (GPE); steviol glycoside and an aromatic amino acid; and steviol glycoside. Also provided herein are methods of making the water soluble solid form compositions.

Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Abstract: The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-? (TGF-?) signal and/or extracellular matrix (ECM).

Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.

Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.

Abstract: Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.

Abstract: Compositions comprising unseparated amnion/chorion derived from the placenta and methods of preparing and using those compositions are provided. Washing or preservation of placental tissue according to the methods of the disclosure may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, increased absorption potential, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the compositions of the invention to the wound.

Abstract: The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe, which may be for use in treating such defects.

Abstract: Techniques are described for extracting key values from a document without having to rely on finding corresponding labels for the target keys within the extracted text of the document. Further the techniques do not rely on knowledge of the correlation between (a) the location of labels within a document, and (b) the location of the key values that correspond to the labels. Key values are extracted from a document by, identifying candidate values within the document, establishing “joint-candidate” sets from those candidate values, and using a trained machine learning mechanism to score each joint-candidate set of values. The highest scoring joint-candidate set is deemed to reflect the correct mapping of candidate values to target keys for the document.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the to compositions also comprise a borate compound.

Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and/or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

Abstract: A patch-type sensor module is provided. A patch-type sensor module according to one embodiment of the present invention comprises: a power supply unit electrically connected with a flexible circuit board; a sensing unit which is mounted on the flexible circuit board and includes a temperature sensor for measuring a user's body temperature; a communication unit which allows power to be supplied using a wake-up function, wherein a pairing with an external communication module is concurrently established when power is supplied, and information measured through the sensing unit is then transmitted to the external communication module; a control unit for controlling operations of the power supply unit, the sensing unit, and the communication unit; and a protection member for preventing the flexible circuit board, the power supply unit, the sensing unit, the communication unit, and the control unit from being exposed to the outside.

Abstract: A build-plate with integrally-formed spinal implant constructs and a method used in forming spinal implant constructs on the build plate and machining the spinal implant constructs formed on the build plate to manufacture spinal implants is provided. The spinal implant constructs can be formed via additive manufacturing processes by adding material to an upper surface of the build plate, and then the spinal implant constructs can be subjected to subtractive manufacturing processes to form the spinal implants.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: A skincare rejuvenation composition, adapted at least for tactile use, consists essentially of a skincare rejuvenation ingredient, a skin exfoliation ingredient, an acidity balancing ingredient, a sunscreen composition and an emulsifier. The skincare rejuvenation ingredient has a first weight percentage, the skin exfoliation ingredient has a second weight percentage, and the acidity balancing ingredient has a third weight percentage, whereby each of the first weight percentage, the second weight percentage, and the third weight percentage are substantially equal. As an example, the skincare rejuvenation ingredient may be retinol, the skin exfoliation ingredient may be glycolic acid, and the acidity balancing ingredient may be hyaluronic acid.

Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.

Abstract: A photocatalyst can be regenerated with increasing efficiency, turnover number and turnover frequency in the presence of air by irradiating the photocatalyst with a first range of wavelengths of light that excite the photocatalyst to an intermediate and irradiating the intermediate with a second range of wavelengths of light that turns the intermediate to the photocatalyst.

Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. The invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.